JPRN-jRCTs052180193进行中（未招募）4 期
ShorT and OPtimal duration of Dual AntiPlatelet Therapy-2 study for patients with ACS - STOPDAPT-2 ACS
Ono Koh0 个研究点目标入组 3,000 人开始时间: 2019年3月26日最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 3,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Patients who have undergone PCI with the everolimus-eluting cobalt-chromium stent (CoCr-EES, XienceTM) in the setting of ACS (STEMI, NSTEMI, or UA) and have not experienced major complications (death, MI, stroke, or major bleeding) during hospital stay for treatment
- •2) Patients who are capable of oral dual antiplatelet therapy consisting of aspirin and a P2Y12 receptor antagonist
排除标准
- •1) Patients requiring oral anticoagulants
- •2) Patients with medical history of intracranial hemorrhage
- •3) Patients who have experienced serious complications (MI, stroke, and major bleeding) during hospital stay post-PCI
- •4) Patients with DES other than Xience implanted in PCI performed at the time of enrollment.
- •5) Patients with coronary bioabsorbable vascular scaffolds (BVS) implanted prior to or at the time of enrollment (including implantation cases in clinical trial)
- •6) Patients confirmed to have no tolerability to clopidogrel before enrollment
- •7) Patients requiring continuous administration of antiplatelet drugs (PDE3 inhibitors, prostaglandin preparations, etc.) other than aspirin and P2Y12 receptor antagonists (prasugrel, clopidogrel, and ticlopidine) at the time of enrollment
研究者
相似试验
已完成
不适用
ShorT and OPtimal duration of Dual AntiPlatelet Therapy studycoronary artery diseaseJPRN-UMIN000008878Kyoto University Hospital1,500
进行中（未招募）
4 期
ShorT and OPtimal duration of Dual AntiPlatelet Therapy-3 studyIschemic heart disease, stable angina, myocardial infarctionJPRN-jRCTs052200114Ono Koh6,000
进行中（未招募）
1 期
Optimal duration of dual anti-platelet therapy in patients undergoing endovascular revascularization of the superficial femoral artery.Patients with diagnosis of lower limbs PAOD, ranging from stage 2 to 5 according to Rutherford classification and lesions of the SFA treated by endovascular revascularizationMedDRA version: 20.0Level: LLTClassification code 10016430Term: Femoral artery stenosisSystem Organ Class: 100000004866EUCTR2018-000532-94-ITFONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO78
进行中（未招募）
不适用
Optimal duration of dual antiplatelet therapy after stent-assisted coiling of unruptured intracranial aneurysms: A prospective randomized multicenter trialDiseases of the circulatory systemKCT0006651Seoul National University Bundang Hospital528
招募中
不适用
DURATIODiseases of the circulatory systemKCT0004407Seoul National University Bundang Hospital4,748